A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants
An Open-label, Single-arm, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HRS-1301 Tablets on the Pharmacokinetics of Midazolam and Atorvastatin Calcium Tablets in Healthy Participants
This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital of Shandong University
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subjects must be aged ≥ 18 years and ≤ 55 years on the day of signing the informed consent form (ICF);
- At screening, body mass index (BMI) must be ≥ 19.0 kg/m² and < 28 kg/m², with body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females;
- Physical examination, vital signs, electrocardiogram (ECG), posteroanterior and lateral chest X-ray/CT, abdominal ultrasound, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and thyroid function) were normal or abnormal but of no clinical significance;
- Female participants must not be pregnant or lactating and must have negative pregnancy test results prior to investigational drug administration; participants must have had no unprotected sexual intercourse within two weeks prior to screening; female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with the contraception requirements for the duration specified in the protocol and have no plans to donate sperm or eggs;
- Subjects who understand the study procedures and methods, voluntarily agree to participate in this trial, and provide written informed consent (ICF).
Exclusion Criteria:
- Subjects with previous medical history or current diagnosis of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, infectious, immunological, malignant neoplastic, neurological, or psychiatric/metabolic disorders/dysfunctions, or any other disease;
- Subjects who have gastrointestinal, hepatic, renal, or other known diseases that may affect drug absorption, distribution, metabolism, or excretion, or that may reduce compliance;
- Subjects who have experienced severe trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial period;
- Subjects with a history of specific allergies, or with an allergic constitution, or with known hypersensitivity to any component of the investigational drug;
- Subjects who have used any medication within 2 weeks prior to screening, or who are still within 5 half-lives of any medication at the time of screening;
- Subjects who have participated in any other clinical trial of a drug or medical device within 3 months prior to screening, or who are still within 5 half-lives of a prior investigational drug at the time of screening;
- Subjects who have donated blood ≥ 200 mL or experienced significant blood loss (≥ 400 mL) within 4 weeks prior to screening, or who have received a blood transfusion within 8 weeks prior to screening;
- Subjects who have received a live (attenuated) vaccine within 4 weeks prior to screening or plan to receive such a vaccine during the trial period.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: HRS-1301 and Midazolam or Atorvastatin Group
HRS-1301 tablets and Midazolam oral solution or Atorvastatin Calcium tablets, specified dose on specified days. |
HRS-1301 tablets. Atorvastatin Calcium tablets. Midazolam oral solution. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum observed plasma concentration (Cmax)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Maximum observed plasma concentration (Cmax)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to reach maximum observed concentration (Tmax)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam and 1-hydroxymidazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Terminal elimination half-life (t1/2)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam and 1-hydroxymidazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Apparent clearance (CL/F)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam and 1-hydroxymidazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Apparent volume of distribution (Vz/F)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of Midazolam 1-hydroxymidazolam when administered alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Maximum observed plasma concentration (Cmax)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of 1-hydroxymidazolam following administration of midazolam alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of 1-hydroxymidazolam following administration of midazolam alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Tijdsspanne: Up to 15 days.
|
Plasma pharmacokinetics (PK) parameters of 1-hydroxymidazolam following administration of midazolam alone and in combination with HRS-1301 tablets. |
Up to 15 days.
|
|
Apparent volume of distribution (Vz/F)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin and 2-Hydroxy Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Apparent clearance (CL/F)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin and 2-Hydroxy Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Time to reach maximum observed concentration (Tmax)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin 2-Hydroxy Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Terminal elimination half-life (t1/2)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of Atorvastatin and 2-Hydroxy Atorvastatin when administered alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Maximum observed plasma concentration (Cmax)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of 2-Hydroxy Atorvastatin following administration of atorvastatin alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of 2-Hydroxy Atorvastatin following administration of atorvastatin alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)
Tijdsspanne: Up to 18 days.
|
Plasma pharmacokinetics (PK) parameters of 2-Hydroxy Atorvastatin following administration of atorvastatin alone and in combination with HRS-1301 tablets. |
Up to 18 days.
|
|
Incidence and severity of adverse events (AEs)
Tijdsspanne: Up to 22 days.
|
Safety and Tolerability. |
Up to 22 days.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Metabole ziekten
- Dyslipidemie
- Stoornissen in het metabolisme van lipiden
- Voedings- en stofwisselingsziekten
- Hyperlipidemie
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Vetzuren
- Lipiden
- Azoles
- Benzazepines
- Pyrroles
- Heptaanzuren
- Benzodiazepines
- Atorvastatine
- Midazolam
Andere studie-ID-nummers
Andere studie-ID-nummers
- HRS-1301-105
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .